Medicine & Life Sciences
ALN-PCS
100%
Myocardial Infarction
74%
LDL Cholesterol
40%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
37%
Mortality
36%
Acute Coronary Syndrome
33%
Coronavirus
27%
Placebos
24%
ST Elevation Myocardial Infarction
23%
Takotsubo Cardiomyopathy
22%
Proprotein Convertase 9
20%
Percutaneous Coronary Intervention
20%
Safety
19%
Survival
19%
Chest Pain
18%
Coronary Artery Disease
18%
Therapeutics
17%
Electrocardiography
17%
Randomized Controlled Trials
16%
inclacumab
15%
Hospital Mortality
14%
dalcetrapib
14%
Lipids
13%
Population
12%
Coronary Artery Bypass
12%
Cardiovascular Diseases
12%
Intensive Care Units
11%
Bundle-Branch Block
11%
Non-ST Elevated Myocardial Infarction
11%
Infarction
10%
Mitral Valve
10%
Confidence Intervals
10%
Registries
10%
Heart Failure
9%
Hospitalization
9%
Cardiogenic Shock
9%
Hyperlipoproteinemia Type II
8%
Coronary Care Units
8%
Echocardiography
8%
Kidney
8%
Cholesterol
7%
P-Selectin
7%
Small Interfering RNA
7%
Research Ethics Committees
7%
Heart Arrest
7%
Angioplasty
7%
Endothelins
7%
roxifiban acetate
7%
Secondary Prevention
7%
Hip Fractures
6%